Impact of thyroid autoimmunity on the cumulative live birth rates after IVF/ICSI treatment cycles

Table 3 Comparison of cumulative live birth outcomes between TAI and control groups

Group	TAI group			Control group			OR (95% CI)	Adjusted OR (95% CI)
Group	No. of patients	No. of LB	CLBR (%) ^a	No. of patients	No. of LB	CLBR (%)	OR (95% CI)	Adjusted OR (95% CI)
Total	2603	1316	50.6	10,193	5316	52.1	0.94 (0.86–1.02)	0.97 (0.89–1.06) ^*
Male factor only	771	364	47.2	2761	1372	49.7	0.91 (0.77–1.06)	0.93 (0.78–1.09) ^#
Ovulation disorder	429	225	52.4	1623	859	52.9	0.98 (0.79–1.21)	1.03 (0.82–1.29) ^#
Tubal factor	891	492	55.2	3768	2081	55.2	1.00 (0.86–1.16)	1.03 (0.88–1.20) ^#
Endometriosis	197	85	43.1	842	429	51.0	0.73 (0.53–0.99)	0.74 (0.53–1.02) ^#
Unexplained	315	150	47.6	1199	575	48.0	0.99 (0.77–1.27)	1.03 (0.79–1.36) ^#

LB, live birth; CLBR, cumulative live birth rate; OR, odds ratio
^a CLBR: cumulative live birth was defined as the delivery of one or more living infants in the first and subsequent frozen-thawed cycles. The cumulative live birth rate was calculated as the number of cumulative live births divided by the number of COS cycles
^* The multivariate model was adjusted for age, body mass index, cause of infertility, FT4, TSH, COS protocols, type of transfer (fresh vs. frozen), type of transferred embryo (cleavage-stage embryo vs. blastocyst), and fertilization method (IVF vs. ICSI).
^#The multivariate model was adjusted for age, body mass index, FT4, TSH, COS protocols, type of transfer (fresh vs. frozen), type of transferred embryo (cleavage-stage embryo vs. blastocyst), and fertilization method (IVF vs. ICSI).

ISSN: 1471-2393